Dolutegravir study

July 30, 2012

A 48-WEEK trial evaluating the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1 infection, has found that the proportion of study participants who were virologically suppressed (HIV-1 RNA 100,000 c/mL), the response rates were 82% for DTG vs. 75% for RAL. Prespecified secondary analyses also supported non-inferiority of dolutegravir to raltegravir; the proportion of subjects without treatment-related discontinuations was 93% on dolutegravir and 92% on raltegravir. Median CD4 increases were also similar in both groups (+230 cells/ mm3). Virologic failure was also found to occur in 5% of DTG subjects and 7% of RAL subjects.

The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 12

Other recent headlines

PD breaking news – Pharmacists to administer NIP vaccinations in aged care
Saturday | Apr 20 2024

Industry stakeholders welcome government announcement. Community pharmacists will be able to provide free flu vaccinations within…

PD breaking news – Top Western Australian talent honoured
Saturday | Apr 20 2024

Vital roles and contributions in healthcare made by outstanding pharmacists recognised. Last night in Perth, the…

Legal action for Montu
Friday | Apr 19 2024

MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.

SEARCH PHARMACY DAILY

Featured video
MORE VIDEOS

Recent issues

PD for Fri 19 Apr 2024
PD for Thu 18 Apr 2024
PD for Wed 17 Apr 2024
PD for Tue 16 Apr 2024
PD for Mon 15 Apr 2024
SEE MORE ISSUES

INDUSTRY JOB VACANCIES

Pharmacist in Charge – SA
Pharmacist Manager – WA
Compounding Pharmacist – Melbourne
Pharmacist in Charge – QLD North
Pharmacist – Sydney North
SEE MORE JOBS

Pharmacy Daily is Australia's favourite online publication dedicated to the pharmacy industry. The publication launched in March 2007 and is distributed every day by email to pharmacists across the country.

PHARMACY DAILY NEWS
Headlines

Jobs

New Products

Events Calendar

FEEDS
News Items RSS feed

PD Issues RSS feed

All content RSS feed

Content & Media
Pharmacy Daily TV

OUR SITES
Sitemap

Travel Daily

Travel Bulletin

Cruise Weekly

Business Events News

Pharmacy Daily

ADVERTISE WITH US
Advertise in Pharmacy Daily

Privacy

ADMIN
Log in

SUBSCRIBE
Sign up for FREE

Subscription Information

"Water, air, and cleanness are the chief articles in my pharmacy." - Napoleon Bonaparte

Copyright © 2018 Pharmacy Daily

Subscribe to Pharmacy Daily now!

FREE Pharmacy Daily subscription - never miss another story!

Name*
First Last
Email*

Profession
Company

Address
City State / Province / Region ZIP / Postal Code Country

By submitting this form I hereby certify that I understand that Pharmacy Daily is a publication for health professionals.
Email
This field is for validation purposes and should be left unchanged.

to top

Pharmacy Daily | Dolutegravir study

Dolutegravir study

Other recent headlines

PD breaking news – Pharmacists to administer NIP vaccinations in aged care

PD breaking news – Top Western Australian talent honoured

Legal action for Montu

SEARCH PHARMACY DAILY

Featured video

Recent issues

INDUSTRY JOB VACANCIES